UF Health is using the knowledge gained from pharmacogenomics research to advance health care for our patients. Pharmacogenetic testing provides information about a person’s genetic profile that can be used to help identify the right medicine and the right dose, ideally before a patient starts taking a medication. UF Health providers at hospitals and clinics in Gainesville and Jacksonville are using genetic information alongside a patient’s medical history to inform treatment decisions in areas such as cancer, heart disease, gastrointestinal disorders and pain management.
UF Health operates one of the nation’s first outpatient pharmacogenomics consultation services. The service brings pharmacogenomic consultations to primary care and is available to UF Health internal medicine patients.
CYP2C19 testing was implemented to predict clopidogrel response in patients undergoing percutaneous coronary intervention at UF Health Shands Hospital.
TPMT genetic testing was implemented to predict response for patients taking a group of drugs known as thiopurines. Adult and pediatric patients with certain types of bowel or joint disorders and acute lymphoblastic leukemia commonly take thiopurines.
IFNL3 testing was implemented to predict the PEG IFN-α-based drug regimen response for gastroenterology patients.
CYP2D6 testing was implemented to predict the response of pain management patients taking multiple opioids including tramadol, codeine, hydrocodone and oxycodone.
CYP2C19 testing was implemented to predict clopidogrel response in patients undergoing percutaneous coronary intervention at UF Health Jacksonville
CYP2D6 and CYP2C19 testing was implemented to predict response for psychiatric patients taking a group of drugs known as selective serotonin reuptake inhibitors, or SSRIs.
CYP2C19 testing was implemented to predict response for gastroenterology patients taking a group of drugs known as proton pump inhibitors.
What is Pharmacogenetics?
Pharmacogenetics can affect response, increase effectiveness and decrease side effects to different medications.
The Future of Precision Medicine at UF Health
Beginning in 2019, the UF Health Precision Medicine Program will launch a multi-gene pharmacogenetics panel developed by UF Health Pathology Laboratories. It will examine multiple drugs, multiple genes and, eventually, diseases to personalize drug therapy and disease risk assessment around an individual’s genetic profile.